News Headlines

Display #
Title
Lots of sleep tied to worse breast cancer survival odds
Roche’s Alecensa notches trial win against Pfizer’s Xalkori
Phase III study shows Roche's Alecensa was superior to crizotinib in a specific type of lung cancer
Dalian Wanda to invest $10 billion in China healthcare hub
The first live-attenuated vaccine candidate completely protects against Zika infection
Stada Accepts $5.6 Billion Takeover Offer
Three Drug Giants That Boasts the Best Pipelines
OncoMed sinks as cancer drug fails
Pancreatic Cancer Pathway Identified; Discovery May Broach New Era of Effective Immunotherapies for the Deadliest Major Cancer
Medtronic recalls devices used to manage fluid build-up in the brain
Four-Person Biotech Pens R&D Deal Worth $1 Billion With Drug Giant Novartis
Towards a safe and scalable cell therapy for type 1 diabetes by simplifying beta cell differentiation
Johnson & Johnson Forges Peptide Discovery Pact Worth $1.5 Billion With Japanese Biopharma Peptidream
Takeda Splits Off a Range of Businesses to Focus on R&D
EMA clears Actelion’s Uptravi after safety review
FDA rejects application for diabetes drug labels
FDA Approves New Indications for Harvoni. Sovaldi
Trump nominee to lead FDA questioned on ties to pharma industry
Experts want special clinics to prescribe ketamine as antidepressant
FDA allows marketing of first direct-to-consumer tests that provide genetic risk information for certain conditions
Elizabeth Holmes Now Owes Theranos $25 Million
A one-two punch hits pancreatic cancer where it hurts
Regeneron Announces Evinacumab has Received FDA Breakthrough Therapy Designation for Homozygous Familial Hypercholesterolemia (HoFH)
Mallinckrodt resigns membership from PhRMA
House panel to consider tweaks to healthcare bill before recess
FDA allows marketing of DTC tests for diseases
Consulting at McCann Health Appoints Two Execs
Novartis to strengthen R&D pipeline by in-licensing ECF843 for ophthalmic indications
New drug delivery system shows promise for fighting solid tumors
Phase III ALUR study supports the use of Roche’s Alecensa for people with advanced ALK-positive lung cancer